Go Pro
NASDAQ:CLVR

Clever Leaves (CLVR) Stock Price, News & Analysis

Clever Leaves logo

About Clever Leaves Stock (NASDAQ:CLVR)

Key Stats

Today's Range
N/A
50-Day Range
$0.0001
$0.0101
52-Week Range
N/A
Volume
N/A
Average Volume
3,633 shs
Market Capitalization
$18 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clever Leaves, Inc. (NASDAQ: CLVR) is a vertically integrated cannabis company specializing in the cultivation, extraction and distribution of pharmaceutical-grade medical cannabis. With production facilities strategically located in Colombia and Portugal, the company leverages favorable climates and stringent Good Manufacturing Practice (GMP) standards to produce a range of cannabinoid formulations for global markets. Its product portfolio includes dried flower, purified cannabinoids and custom formulations designed to meet regulatory requirements in key jurisdictions.

Originally founded in 2019, Clever Leaves completed a business combination with a special purpose acquisition company in 2021, resulting in its Nasdaq listing. Since then, the company has scaled its operations through the development of advanced cultivation technologies, tissue-culture propagation techniques and a state-of-the-art extraction facility in Portugal. Clever Leaves is focused on quality assurance, analytical testing and traceability protocols to support its mission of providing consistent, research-driven cannabis products.

Clever Leaves serves diverse markets across Europe, Latin America and Canada, supplying medical cannabis to patients and pharmaceutical partners. The company holds cultivation, manufacturing and distribution licenses in Colombia and Portugal, and it actively pursues product registrations and import approvals in regulated jurisdictions. Through collaborations with local clinical research organizations and strategic off-take agreements, Clever Leaves is working to expand patient access to cannabinoid-based therapies.

Guided by an experienced management team with backgrounds in agriculture, pharmaceutical manufacturing and international distribution, Clever Leaves seeks to establish itself as a global leader in the cannabis industry. By combining best-in-class cultivation practices, quality compliance and scientific research, the company aims to deliver scalable solutions that address evolving patient needs and regulatory landscapes.

AI Generated. May Contain Errors.

Receive CLVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clever Leaves and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLVR Stock News Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Clever Leaves Holdings Inc.
See More Headlines

CLVR Stock Analysis - Frequently Asked Questions

Clever Leaves's stock reverse split before market open on Friday, August 25th 2023.The 1-30 reverse split was announced on Thursday, August 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of CLVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clever Leaves investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Salesforce (CRM).

Company Calendar

Today
8/14/2026
Next Earnings (Estimated)
8/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CLVR
CIK
1819615
Fax
N/A
Employees
560
Year Founded
2016

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$17.42 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.02 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,755,000
Free Float
1,611,000
Market Cap
$18 thousand
Optionable
No Data
Beta
3,816.13

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:CLVR) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners